Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Regeneron PharmaceuticalsLTS:0R2M +0.59%87 PB Ratio is 2.26 as of Jul. 21, 2026, which is 43% below its 10-year median of 3.99. GuruFocus rates LTS:0R2M with a GF Score™ of 87/100 and a GF Value™ of $910.39 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 1,229 Biotechnology companies, Regeneron Pharmaceuticals ranks better than 58.83% on this metric.
The historical rank and industry rank for Regeneron Pharmaceuticals's PB Ratio or its related term are showing as below:
LTS:0R2M'
s PB Ratio Range Over the Past 10 Years
Min: 1.81 Med: 3.99 Max: 11.3
Current: 2.25
During the past 13 years, Regeneron Pharmaceuticals's highest PB Ratio was 11.30. The lowest was 1.81. And the median was 3.99.
LTS:0R2M's PB Ratio is ranked better than 58.83% of 1229
companies
in the Biotechnology industry
Industry Median: 2.79
vs LTS:0R2M: 2.25
During the past 12 months, Regeneron Pharmaceuticals's average Book Value Per Share Growth Rate was 10.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 21.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 25.30% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Regeneron Pharmaceuticals was 87.30% per year. The lowest was -20.60% per year. And the median was 13.90% per year.
Back to Basics: PB Ratio
Regeneron Pharmaceuticals (LTS:0R2M) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Regeneron Pharmaceuticals PB Ratio Related Terms
Regeneron Pharmaceuticals PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Regeneron Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Regeneron Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Regeneron Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Regeneron Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Regeneron Pharmaceuticals (LTS:0R2M) has a PB Ratio of 2.26 as of Jul. 21, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regeneron Pharmaceuticals and its competitors. This is 43% below median its historical median of 3.99. Over the past decade, Regeneron Pharmaceuticals' PB Ratio has ranged from 1.81 to 11.30. According to the industry distribution chart, Regeneron Pharmaceuticals ranks #506 out of 1229 companies in the Biotechnology industry, placing it in the top 41.2%.
Is Regeneron Pharmaceuticals' PB Ratio too high?
Regeneron Pharmaceuticals' current PB Ratio of 2.26 is 43% below median its 10-year median of 3.99. Over the past 10 years, this metric has ranged from a low of 1.81 to a high of 11.30. The Biotechnology industry median PB Ratio is 2.79. Regeneron Pharmaceuticals' value of 2.26 is 19% below this industry median. Based on the distribution chart, Regeneron Pharmaceuticals ranks #506 out of 1229 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Regeneron Pharmaceuticals has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Regeneron Pharmaceuticals' PB Ratio compare to ALNY and RVMD?
According to the Biotechnology industry distribution chart, Regeneron Pharmaceuticals ranks #506 out of 1229 companies for PB Ratio. This puts Regeneron Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.79. Regeneron Pharmaceuticals' value of 2.26 is 19% below this benchmark. Historically, Regeneron Pharmaceuticals' own PB Ratio has ranged from 1.81 to 11.30 over the past decade. While the company's 10-year median is 3.99 vs. the industry median of 2.79, Regeneron Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.79, based on 1,229 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Regeneron Pharmaceuticals's current PB Ratio of 2.26 is 19% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Regeneron Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.79 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Regeneron Pharmaceuticals's current PB Ratio is 2.26, which is 43% below median its own 10-year median of 3.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regeneron Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals (LTS:0R2M) is currently considered Modestly Undervalued. The stock's GF Value™ is $910.39, compared to a current price of $676.38 — trading 25.7% below its estimated fair value. The current PB Ratio is 2.26, which is 43% below median its 10-year median of 3.99 and 19% below the Biotechnology industry median of 2.79. Regeneron Pharmaceuticals' overall GF Score™ is 87/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Regeneron Pharmaceuticals (LTS:0R2M), the current PB Ratio is 2.26 as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Regeneron Pharmaceuticals (LTS:0R2M) Overvalued in 2026?
Based on GuruFocus' analysis, Regeneron Pharmaceuticals stock appears to be undervalued.
The current stock price of $676.38 is trading 25.7% below its estimated GF Value™ of $910.39.
GuruFocus considers Regeneron Pharmaceuticals to be Modestly Undervalued.
Key valuation signals for LTS:0R2M:
PB Ratio: 2.26 (43% below median its 10-year median of 3.99)
GF Value™: $910.39 vs. price of $676.38 (25.7% below fair value)
Industry Position: 19% below the Biotechnology median (#506 of 1229)
No single metric tells the full story. See the LTS:0R2M stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
87GF Score
Get the complete analysis for LTS:0R2M
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2M has been successfully added to your 
